3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Docetaxel
35
pembrolizumab
32
Nivolumab
27
enzalutamide
20
Prednisone
20
Sunitinib
16
Cyclophosphamide
16
aldesleukin
14
Zoledronic Acid
13
Interleukin-2
13
Gemcitabine
13
Bevacizumab
13
Specimen Handling
12
Ipilimumab
12
Radiosurgery
11
Everolimus
11
Androgen Antagonists
11
Abiraterone Acetate
11
fludarabine
10
Sorafenib
10
Radiotherapy
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
pazopanib
9
abiraterone
9
Doxorubicin
8
Carboplatin
8
Biopsy
8
avelumab
7
temsirolimus
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Clinical Trials, Phase II as Topic
×
Genitourinary
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled